about
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatmentProgress and prospects in pharmacogenetics of antidepressant drugs.Pharmacogenetics of antidepressant response.Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.Pharmacogenetics of antidepressantsGenome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway.Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression.HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.Mechanisms of antidepressant action: an integrated dopaminergic perspective.Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism.Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.Pharmacogenetics in major depression: a comprehensive meta-analysis.A model to investigate SNPs' interaction in GWAS studies.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors.Genetics of long-term treatment outcome in bipolar disorder.Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics.Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression.Clinical features and drug induced side effects in early versus late antidepressant responders.Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial.Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples.Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression.Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders.Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.Predictors of switch from depression to mania in bipolar disorder.HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia.Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment.DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.Shared genetics among major psychiatric disorders.Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples.Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials
P50
Q27015830-022E417E-ED06-4F95-A957-41ED187420B6Q30249569-F72C29E1-6445-4DBF-9DFF-C7FD37FF46C2Q34155796-9350405F-42A3-456A-BB27-ADC85A4054F7Q34424865-7A258AC9-FA43-424C-8F2F-671C94B7966BQ35026088-BC4709F4-05B2-4A46-9360-86C831722981Q35993192-DF4EBB5F-23D9-4C0D-9186-6A05D18F0140Q36033253-070533E4-C6DA-4546-B345-63249ED50CE8Q36941592-0BF30A0E-918E-4E9E-BB61-6297EF55E409Q36950578-82595B70-E90B-4088-83CA-7F2FEFA56B59Q37852837-A83CA67E-0F85-4F5D-895A-0ED7525DE3E6Q37898706-A09F5D11-5DA4-4AEE-A54D-06243A4F2983Q37964231-1DBACFEA-4302-43DC-85E3-EE829EAF03D2Q38121519-06148FD4-5A4A-4083-A434-F24BA5849775Q38444087-AC130233-ABAC-4F4F-B9C3-59A5DF8A165AQ38454066-74E8DF2E-474A-4987-99B0-0450E5046405Q38470023-C2780EAE-8030-420A-838F-DDE8EE76989BQ38484370-A5E17038-7B44-467F-B52E-C383667AFDA3Q38715407-E97F5FDE-AB8C-4CE6-A670-B9812211AB74Q39928385-24622EC5-5F1C-477D-BC44-AD260BCD26C4Q40616934-03AAFBDB-651E-40CE-8C45-CCA5AA7FED21Q40898013-87823F71-A7C1-4873-9D2F-0FE10AF2705CQ41477541-EBE32624-F55A-43AA-BA76-92ACF4D9C5D4Q42350910-35887D59-9FB9-4C6A-9A59-35994741D210Q43474825-CE75CA7C-F022-4356-9A88-38E257860940Q45754167-BE168A75-DA7E-4BEA-9725-5293DE543AE4Q45945144-5DF1C2C2-DEF6-4585-B94C-B6D2C15512ABQ45985388-5C9DE78A-046B-416F-A442-B0058E09A9FEQ46122791-1DEC9E12-6000-4A82-A21A-112F5627FE48Q46367268-C3B8E8C8-6E47-4A3A-B2A4-36C5B3A38ECDQ46434375-5808AC03-FB76-4797-BE0F-0EA8B6F6FDEAQ46519736-44A401E2-EE4D-4B90-B8D6-2A6538AEE3F8Q47389044-7A233350-01DF-4D85-9559-375021832245Q48083943-C93BDC2B-8483-44C9-98F5-217B00262BD1Q48087061-BC57579D-3213-4BA2-ACAB-79F3D7140A70Q48224587-28EF79CD-A28B-4CB0-8FD9-5C4B741FFDBEQ48250692-5F90A7B4-CDAE-4E2A-8CF1-3CE78E4B2FD9Q48506503-F6B1E142-20AE-4945-993E-E397A6AA0738Q48600739-10E8E618-FECD-426E-BE40-BE6B7390352CQ51300430-7352E602-E20B-42A7-B7C9-35AA83FBBE8BQ56339819-4C7BCDEC-EC5F-4FD9-A194-CA370BF7A2FA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chiara Fabbri
@ast
Chiara Fabbri
@en
Chiara Fabbri
@es
Chiara Fabbri
@nl
Chiara Fabbri
@sl
type
label
Chiara Fabbri
@ast
Chiara Fabbri
@en
Chiara Fabbri
@es
Chiara Fabbri
@nl
Chiara Fabbri
@sl
prefLabel
Chiara Fabbri
@ast
Chiara Fabbri
@en
Chiara Fabbri
@es
Chiara Fabbri
@nl
Chiara Fabbri
@sl
P106
P21
P31
P496
0000-0003-0276-7865